DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Kilitch Drugs (India) Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·8 Oct 2026, 11:21 am

Kilitch Drugs India

Kilitch Drugs (India) Limited has filed a regulatory certificate with stock exchanges. This document is filed under SEBI's (Depositories and Participants) Regulations, 2018. The company has confirmed that it has complied with the specified requirements for the depository system. This filing is a routine administrative step that ensures the company's shares are eligible for trading and settlement on the exchanges.

For investors, this news is a standard compliance update and does not indicate any major operational change. It confirms that the company is maintaining proper records with the depositories. While this filing does not directly impact the company's financial performance or business prospects, it is a positive signal regarding the company's adherence to regulatory norms.

Investors should monitor this stock for any further announcements or price movements. The focus should remain on the company's core business performance and quarterly results. This filing is a low-risk event and does not alter the fundamental view of the company's investment case.